Preferred Name | Dabrafenib | |
Synonyms |
GSK-2118436 Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- BRAF Inhibitor GSK2118436 GSK-2118436A DABRAFENIB Dabrafenib GSK2118436 |
|
Definitions |
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82386 |
|
Accepted_Therapeutic_Use_For |
metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation |
|
CAS_Registry |
1195765-45-7 |
|
Chemical_Formula |
C23H20F3N5O2S2 |
|
code |
C82386 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc |
|
DEFINITION |
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. |
|
Display_Name |
Dabrafenib |
|
FDA_UNII_Code |
QGP4HA4G1B |
|
FULL_SYN |
GSK-2118436 Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- BRAF Inhibitor GSK2118436 GSK-2118436A DABRAFENIB Dabrafenib GSK2118436 |
|
Has_Salt_Form | ||
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Dabrafenib |
|
Legacy Concept Name |
BRAF_Inhibitor_GSK2118436 |
|
Maps_To |
Dabrafenib |
|
NCI_Drug_Dictionary_ID |
641977 |
|
PDQ_Closed_Trial_Search_ID |
641977 |
|
PDQ_Open_Trial_Search_ID |
641977 |
|
Preferred_Name |
Dabrafenib |
|
prefixIRI |
Thesaurus:C82386 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C3467876 |
|
subClassOf |